Four people with relapsed or refractory multiple myeloma who received BCMA-directed CAR-T cells engineered inside their own bodies have now been tracked over a longer stretch of time, and the published outcome points to a familiar obstacle: the responses did not hold. The report appears in Nature Medicine, posted online on 6 October 2026.
The journal's summary of the work states plainly that extended follow-up of the four treated patients showed limited duration of response. That is a narrow, carefully bounded claim drawn from a very small group — but it lands squarely on the question that has defined the entire in vivo CAR-T field: whether engineering a patient's T cells from within can deliver the deep, lasting remissions that conventional, laboratory-manufactured CAR-T products have produced in blood cancers.
What the Extended Follow-Up Covers
This paper is not a new trial readout so much as a longer look at a handful of patients. Rather than reporting short-term safety and initial response, the authors followed four individuals with relapsed or refractory multiple myeloma after treatment with in vivo BCMA CAR-T cells, tracking how their disease behaved as time passed.
Multiple myeloma is a cancer of plasma cells, the antibody-producing cells of the bone marrow, and the disease remains treatable but rarely curable, particularly once it has returned after — or stopped responding to — standard regimens. That relapsed and refractory setting is precisely where new cell therapies are tested hardest, because the patients involved have already exhausted many other options.
The distinguishing feature here is the delivery method. The CAR-T cells were not manufactured outside the body and reinfused; they were generated in vivo, meaning the genetic engineering that gives T cells their tumor-targeting receptor happened inside the patient rather than in a specialized production facility.
How In Vivo CAR-T Differs From Conventional Therapy
Conventional CAR-T therapy is a logistics-heavy process. A patient's T cells are collected through apheresis, shipped to a manufacturing site, genetically modified to express a chimeric antigen receptor, expanded into large numbers, tested, frozen, and returned for infusion. That sequence can take weeks, during which a progressing cancer may not wait.
Manufacturing inside the patient
In vivo approaches compress that chain by delivering the engineering instructions directly — typically through a viral or targeted delivery vector — so that the patient's own circulating T cells acquire the receptor on site. If it works, the patient becomes the manufacturing plant. The promise is speed, wider accessibility, and the removal of a costly, capacity-constrained production bottleneck that has limited how many people can receive cell therapy at all.
Reaching the BCMA target
BCMA, or B-cell maturation antigen, is a protein found on the surface of plasma cells and is expressed strongly on myeloma cells, which is why it has become the anchor target for CAR-T and bispecific approaches in this disease. A BCMA-directed receptor gives engineered T cells a handle on the malignant plasma cell population. None of that biology is new; what is new in this line of work is where and how the receptor gets installed.
Why Durability Is the Decisive Question in Myeloma
For any cell therapy in myeloma, the hard part is not always getting an initial response — it is keeping one. Tumors in this disease are adept at evolving, and the persistence of the engineered T cells themselves matters enormously to how long a remission lasts. If the modified cell population contracts too quickly, or if the malignant plasma cells lose or shed the antigen the receptor recognizes, the disease can return.
That dynamic is exactly what makes extended follow-up so important and so unforgiving. A short report can show that engineered cells engaged the target and that disease markers fell. Only time reveals whether the effect was a durable reset or a brief window. In this cohort, the longer view pointed to limited durability.
The result does not undermine the underlying concept so much as identify where the concept still has to prove itself. Persistence, expansion, and antigen escape are the levers that determine long-term performance, and in vivo delivery adds its own variables to that list.
What Four Patients Can and Cannot Show
It is worth being explicit about the limits of a four-patient follow-up, because the temptation to overread early cell therapy data is strong in both directions — toward premature celebration and toward premature dismissal.
- Directional, not definitive. A handful of patients can flag a durability signal worth investigating, but it cannot establish rates of response, resistance, or survival across a population.
- Selection effects. Participants in a relapsed or refractory myeloma study have typically been through multiple prior lines of therapy, and their disease biology may not resemble that of patients treated earlier.
- Delivery variables. In vivo engineering introduces questions — how many T cells actually get modified, how uniformly, and how long they remain functional — that differ in kind from those in ex vivo manufacturing.
- Follow-up length matters. The significance of "limited duration" depends on the interval observed; longer tracking of larger cohorts is what will settle it.
Read together, those caveats mean the appropriate takeaway is a measured one: this is a signal about persistence, not a verdict on the platform.
The Wider Stakes for Cell Therapy
Interest in in vivo CAR-T has grown because it addresses the least glamorous but most limiting part of the current paradigm — the manufacturing pipeline. Complexity, cost, turnaround time, and the specialized centers required to administer apheresis-based therapies all narrow who can be treated. A therapy that could be delivered as an off-the-shelf injection capable of reprogramming T cells on the spot would change the economics and the reach of the entire field.
Myeloma is a sensible proving ground for that ambition, given how well validated BCMA is as a target. But the field's enthusiasm has always run ahead of its durability data. The Nature Medicine follow-up is a reminder that convenient delivery and lasting disease control are separate engineering problems, and that solving the first does not automatically deliver the second.
What to Watch Next
The questions that follow from this report are concrete. Do modified T cells persist measurably months after treatment, and at what levels? Does the approach produce the kind of expansion seen with conventional products? Are retreated or newly treated patients showing the same pattern, and does dose or vector design shift the curve? Larger studies with longer observation windows will determine whether limited durability is an intrinsic feature of in vivo engineering or a parameter that can be tuned.
For now, the honest summary is the one the journal offers: four patients with relapsed or refractory multiple myeloma received in vivo BCMA CAR-T cells, and their responses did not prove lasting. That is a small but useful data point, and it tells the field exactly where the next round of work needs to focus.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
